Vitruvian Partners LLP

LONDON, null · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 13, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$113.3M2026 Q3
Positions8
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.100.0%

Vitruvian Partners LLP reported 8 positions worth $113.3M as of September 30, 2026 (13F filed November 13, 2026). Largest holding: HNGE (38.6%).

8 positions shown
#SymbolCompanyValue ↓% Port.Shares1YYTDSince reported
▸ 1 HNGEHinge Health$43.8M38.62%450,000——+24.7%
▸ 2 MQMarqeta$29.1M25.70%1,713,295——+7.2%
▸ 3 XMTRXometry$15.0M13.25%145,969——+18.7%
▸ 4 GLBEGlobal-E Online$8.4M7.37%210,209——+4.2%
▸ 5 CARGCarGurus$6.9M6.05%220,000——+13.3%
▸ 6 MXCTMaxcyte$5.6M4.99%5,043,356———
▸ 7 WSEWise$3.2M2.83%281,277——+2.4%
▸ 8 RXSTRxSight$1.4M1.21%278,865——+8.2%

Read the 2026-Q2 quarterly report · 13F Filing Calendar

🔔 Tell me when this fund files a new 13F

No account needed: in your inbox the morning it is published.

Frequently Asked Questions

What stocks does Vitruvian Partners LLP hold as of Q3 2026?

Vitruvian Partners LLP reported 8 positions worth $113.3M in its Q3 2026 13F filing. Largest positions: HNGE (38.6%), MQ (25.7%), XMTR (13.2%), GLBE (7.4%) and CARG (6.0%).

What did Vitruvian Partners LLP buy in Q3 2026?

No previous quarter is available yet; the comparison appears with the next filing.

What did Vitruvian Partners LLP sell in Q3 2026?

No previous quarter is available yet.

13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.